RT Journal Article
SR Electronic
T1 A Quantitative Characterization of the Spatial Distribution of Brain Metastases from Breast Cancer and Respective Molecular Subtypes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.05.22277116
DO 10.1101/2022.07.05.22277116
A1 Mahmoodifar, Saeedeh
A1 Pangal, Dhiraj J.
A1 Cardinal, Tyler
A1 Craig, David
A1 Simon, Thomas
A1 Tew, Ben Yi
A1 Yang, Wensha
A1 Chang, Eric
A1 Yu, Min
A1 Neman, Josh
A1 Mason, Jeremy
A1 Toga, Arthur
A1 Salhia, Bodour
A1 Zada, Gabriel
A1 Newton, Paul K.
YR 2022
UL http://medrxiv.org/content/early/2022/07/07/2022.07.05.22277116.abstract
AB Brain metastases (BM) remain a significant cause of morbidity and mortality in breast cancer (BC) patients. Specific factors promoting the process of BM and predilection for selected neuro-anatomical regions remain unknown, yet may have major implications for prevention or treatment. Anatomical spatial distributions of BM from BC suggest a predominance of metastases in the hindbrain and cerebellum. Systematic approaches to quantifying BM location or location-based analyses based on molecular subtypes, however, remain largely unavailable. We analyzed stereotactic Cartesian coordinates derived from 134 patients undergoing gamma-knife radiosurgery (GKRS) for treatment of 407 breast cancer BMs to quantitatively study BM spatial distribution along principal component axes and by intrinsic molecular subtype (ER,PR,Herceptin). We corroborated that BC BMs show a consistent propensity to arise posteriorly and caudally, and that Her2+ tumors are relatively more likely to arise medially rather than laterally. To compare the distributions among varying BC molecular subtypes, we used the notion of mutual information, which revealed that the ER-PR-Her2+ and ER-PR-Her2-subtypes showed the smallest amount of mutual information and were most molecularly distinct. Using kernel density estimators, we found a propensity for triple negative BC to arise in more superiorly or cranially situated BMs. BM location maps according to vascular and anatomical distributions using cartesian coordinates to aid in systematic classification of tumor locations were additionally developed. Further characterization of these patterns may have major impacts on treatment or management of cancer patients.Significance The quantitative spatial distribution of breast cancer metastases to the brain, and the effects of breast cancer molecular subtype on distribution frequencies remain poorly understood. We present a novel and shareable workflow for characterizing and comparing spatial distributions of BM which may aid in identifying therapeutic or diagnostic targets and interactions with the tumor microenvironment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPartial funding through the USC Norris Comprehensive Cancer Center's Multi-Level Cancer Risk Prediction Models pilot project award, Molecular, Clinical and Neuro-imaging Determinants of Spatiotemporal Pathogenesis of Cancer-Specific Brain Metastases: Data Analysis and Longitudinal Modeling (12/01/2020-11/30/2021) is gratefully acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:USC Biomedical IRB waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.